Home › Funds › Velan Capital Investment Management LP › LYEL

Velan Capital Investment Management LP position in LYEL

LYELL IMMUNOPHARMA INC · Health Care

Velan Capital Investment Management LP reported holding 15,000 shares of LYEL (LYELL IMMUNOPHARMA INC) in its Q3 2026 13F filing — a position valued at US$147K, representing 0.14% of its reported portfolio and ranking #38 among its reported holdings. Velan Capital Investment Management LP has disclosed LYEL holdings in 3 of the last 3 reported quarters, going back to Q1 2026.

Latest position (Q3 2026)15.00K sh
Reported value held$146.85K
Portfolio Weight0.14%
First reportedQ1 2026
Last changeReduce
Updated2026-11-16

Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR

How Velan Capital Investment Management LP's LYEL position evolved

Velan Capital Investment Management LP first disclosed a stake in LYEL in Q1 2026 at 102,000 shares (US$2.0M). Across 3 filings, Velan Capital Investment Management LP increased the stake 1 time(s), trimmed it 1 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 15,000 shares valued at US$147K — a reduction of -90,000 shares quarter over quarter.. Notable position changes include a 86% trim in Q3 2026 (shares rose 46% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q1 2026 102.00K $2.05M New
Q2 2026 105.00K $1.48M Add
Q3 2026 15.00K $146.85K Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About LYEL and 13F data

LYEL (LYELL IMMUNOPHARMA INC) is a Health Care company. 29 other funds we track also report a position in LYEL — the largest reported positions include ARCH Venture Management, LLC (US$45.5M), GSK plc (US$14.8M), Almitas Capital LLC (US$8.2M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding LYEL

All LYEL fund holders →

FAQ

How long has Velan Capital Investment Management LP held LYEL?

Velan Capital Investment Management LP has disclosed LYEL holdings in 3 of the last 3 reported quarters, going back to Q1 2026.

What is Velan Capital Investment Management LP's current position in LYEL?

As of Q3 2026, Velan Capital Investment Management LP holds 15.00K shares of LYEL (LYELL IMMUNOPHARMA INC), valued at $146.85K, representing 0.14% of its reported portfolio and ranking #38.

Has Velan Capital Investment Management LP been buying or selling LYEL?

In the latest 13F filing (Q3 2026), Velan Capital Investment Management LP reduced its position in LYEL.

Which other funds hold LYEL?

Other major institutional holders of LYEL include ARCH Venture Management, LLC, GSK plc, Almitas Capital LLC, among 29 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.